List | Section | Observation |
---|---|---|
WHO Model List of Essential Medicines (2021) | 6.2.4. Antileprosy medicines | No observations |
PAHO Strategic Fund Medicine List | 2.2. Antileprosy med. |
Others observations: Medicines used in the treatment of leprosy should never be used except in combination. |
List | Section | Observation |
---|---|---|
WHO Model List of Essential Medicines (2021) | 6.2.4. Antileprosy medicines | No observations |
PAHO Strategic Fund Medicine List | 2.2. Antileprosy med. |
Others observations: Medicines used in the treatment of leprosy should never be used except in combination. |
Peru | 6.2.3 Anti-Leprosy | No observations |
Venezuela (incomplete) | List of Generic Medications - Venezuela | No observations |
List | Section | Observation |
---|---|---|
WHO Model List of Essential Medicines (2021) | 6.2.4. Antileprosy medicines | No observations |
PAHO Strategic Fund Medicine List | 2.2. Antileprosy med. |
Others observations: Medicines used in the treatment of leprosy should never be used except in combination. |
Colombia | 01. Leprostatics | No observations |
Bolivia | LINAME 2011 - 2013 | No observations |
Peru | 6.2.3 Anti-Leprosy | No observations |
Ecuador | Essential Medicines List - Ecuador | No observations |
Chile | Essential and Prioritized Medications | No observations |
Venezuela (incomplete) | List of Generic Medications - Venezuela | No observations |
Cuba | 6.2.10 Antituberculosos y antileprosos | No observations |